Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Progress in preventing chemotherapy-induced nausea and vomiting.

Maurie Markman1

  • 1The Cleveland Clinic Taussig Cancer Center, The Cleveland Clinic Foundation, Ohio 44195, USA. markmam@ccf.org

Cleveland Clinic Journal of Medicine
|August 20, 2002
PubMed
Summary

Advances in antiemetic drugs now prevent most acute chemotherapy-induced emesis. However, managing delayed and anticipatory nausea and vomiting remains a significant clinical challenge for patients undergoing chemotherapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The IMMUNO-BIOMAP trial in NSCLC: An adaptive multimodal framework for biomarker-guided care.

Cell reports. Medicine·2026
Same author

Use of ALK Inhibitors in Patients With Nonlung Malignancies Bearing <i>ALK</i> Alteration Prolongs Treatment Duration.

JCO precision oncology·2026
Same author

The critical need for robust decision support in the era of precision cancer therapeutics.

Exploration of targeted anti-tumor therapy·2026
Same author

What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer.

Gynecologic oncology·2022
Same author

Treatment of Patients With Lobular Breast Cancer Harboring Human Epidermal Growth Factor Receptor 2 Mutation With HER2-Directed Therapy.

JCO precision oncology·2022
Same author

Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancersurgery.

Gynecologic oncology reports·2020

Area of Science:

  • Oncology
  • Pharmacology
  • Gastroenterology

Background:

  • Significant progress has been made in understanding the pathophysiology of emesis over the last 20 years.
  • Current antiemetic pharmacotherapies are highly effective in preventing acute chemotherapy-induced emesis (CIE).

Purpose of the Study:

  • To review the current understanding of emesis pathophysiology.
  • To highlight the challenges in managing delayed and anticipatory forms of CIE.

Main Methods:

  • Literature review of emesis pathophysiology.
  • Analysis of current antiemetic drug efficacy.
  • Discussion of clinical challenges in CIE management.

Main Results:

  • Most acute chemotherapy-induced emesis can be prevented with modern antiemetic drugs.

Related Experiment Videos

  • Delayed and anticipatory chemotherapy-induced emesis present persistent management difficulties.

    • Conclusions:

    • While acute CIE is largely manageable, effective strategies for delayed and anticipatory CIE are still needed.
    • Further research into the mechanisms and treatment of refractory CIE is warranted.